ClinicalTrials.gg
WithdrawnNCT05121402Updated May 13, 2022

Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative Colitis

A Phase 2 interventional study of TLL018 and Placebo in Ulcerative Colitis, sponsored by TLL Pharmaceutical, LLC. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-13.

Sponsored by TLL Pharmaceutical, LLC · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Decisions made by senior management of the company

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 615 studies in Colitis, Ulcerative with a site in United States — 116 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.

Enrollment
484th of 499
0 · median 76
Started
2022
with 32 others
Phase 2
146 of 615
25 open now
Registered
440th of 615
by date

Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 484th largest by enrollment of the 499 interventional ones that give a count, is one of 33 that started in 2022, is one of 146 in phase 2, and was the 440th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

116 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 615 studies in Colitis, Ulcerative with a site in United States, or all of them as a file.
02

Study summary

A study to investigate the safety and efficacy of TLL018 compared with placebo in subjects with moderate to severe ulcerative colitis.

Read the detailed description

This is a phase 2, multicenter, randomized, double-blind, parallel dose groups, placebo-controlled dose ranging study to evaluate the safety and efficacy of 3 doses of TLL018 as an induction therapy in subjects with moderate to severe UC.

Eligible subjects will be randomized to receive one of the following treatments: TLL018 low dose, TLL018 middle dose, TLL018 high dose, or placebo. All subjects may remain on a stable dose of conventional therapy used prior to enrollment. Subjects will be assessed for safety, tolerability, and response to treatment. Samples for pharmacokinetics (PK) and pharmacodynamics (PD) biomarker analyses will be collected throughout the study according to the Schedule of Assessments (SoA) for potential correlation to clinical outcomes.

Further participation may continue beyond the initial 8 weeks for another 5-week Extension Period of therapy.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects ≥ 18 and ≤ 75 years of age at baseline.
  • Capable of giving and complying with study procedures.
  • Normal renal function or mild renal impairment as determined by the Investigator following review of clinical laboratory test results.
  • Laboratory and medical history parameters within the protocol-defined ranges.
  • Diagnosis of UC for 90 days or greater prior to baseline, confirmed by colonoscopy during the screening period, with exclusion of current infection, colonic dysplasia, and/or . Appropriate documentation of results consistent with the diagnosis of UC, in the assessment of the Investigator, must be available.
  • Active UC with a full Mayo score of 6 to 12 points and endoscopic subscore of 2 or higher confirmed by central reader.
  • Subject must have received COVID-19 vaccine >2 months before first dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women.
  • history of cardiovascular, hematologic, renal, hepatic, bronchopulmonary, immunologic, lipid metabolism disorders, or drug as determined by the Investigator.
  • Current and/or recent history of a clinically significant infection.
  • Any history of , except for non-melanoma skin cancers (unless it is ).
  • Positive blood screen for (HIV), surface antigen (HBsAg), or antibody.
  • Any condition or finding that in the Investigator's opinion would put the subjects or study conduct at risk if the subjects were to participate in the study.
  • Current diagnosis of Crohn's disease (CD) or diagnosis of indeterminate colitis (IC).
  • Current diagnosis of fulminant colitis and/or toxic megacolon, or active Clostridium difficile colitis.
  • Subject with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.
  • Subject with previous exposure to JAK inhibitor (eg, tofacitinib, baricitinib, filgotinib, upadacitinib).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Low dose TLL018,BID

    Drug: TLL018 all subjects will receive TLL018 for 8 weeks

    Drug: TLL018

  • Experimental
    Middle dose TLL018,BID

    Drug: TLL018 all subjects will receive TLL018 for 8 weeks

    Drug: TLL018

  • Experimental
    High dose TLL018,BID

    Drug: TLL018 all subjects will receive TLL018 for 8 weeks

    Drug: TLL018

  • Placebo comparator
    Placebo

    Placebo twice daily for 8 weeks.

    Other: Placebo

Interventions

  • DrugTLL018

    a TYK2/JAK1 inhibitor

  • OtherPlacebo

    a TLL018 Placebo

06

What researchers measure

Primary outcomes

  1. Percentage of subjects who achieved clinical remission per adapted Mayo score at Week 8

    Time frame: Baseline to Week 8

  2. Number of treatment-emergent adverse events (TEAEs)

    TEAE defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: Up to 8 weeks

  3. Incidence of Adverse Events (AEs) and Adverse Events of Special Interest (AESIs)

    Time frame: Up to 8 weeks

  4. Number of Participants With Clinically Significant Changes in clinical laboratory data

    Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.

    Time frame: Up to 8 weeks

  5. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, respiratory rate, weight and height. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported.

    Time frame: Up to 8 weeks

  6. Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings

    Clinically significant ECG criteria included QT interval corrected using the Fridericia's formula (QTCF) value 450 msec and 30\<=change\<60.

    Time frame: Up to 8 weeks

Secondary outcomes

  1. Percentage of subjects with endoscopic improvement at Week 8

    Time frame: Week 8

  2. Percentage of subjects with endoscopic remission at Week 8

    Time frame: Week 8

  3. Percentage of subjects achieving clinical response per adapted Mayo score at Week 8

    Time frame: Week 8

  4. Percentage of subjects achieving clinical response per partial adapted Mayo score at Week 2

    Time frame: Week 2

  5. Percentage of subjects who achieved histologic-endoscopic mucosal improvement (as defined by endoscopic subscore and Geboes score) at Week 8

    Time frame: Week 8

  6. Percentage of subjects with mucosal healing (as defined by the endoscopic and histologic variables) at Week 8

    Time frame: Week 8

  7. Percentage of subjects who achieved histologic improvement (as defined by Geboes score) at Week 8

    Time frame: Week 8

  8. Percentage of subjects who reported no bowel urgency (as monitored electronically via a handheld device) at Week 8

    Time frame: Week 8

  9. Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Score

    The IBDQ is used to measure disease specific quality of life on a 32 Likert-scaled items questionnaire. The IBDQ scale contains 4 component subscales: bowel symptoms, systemic symptoms, emotional function and social function with scores ranging from 10 to 70, 5 to 35, 12 to 84 and 5 to 35 respectively and the total score ranges from 32 to 224. Higher scores indicate better health related quality of life.

    Time frame: Baseline to Week 8

  10. Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Questionnaire Score

    The FACIT system is a collection of quality of life (QOL) questionnaires targeted to the management of cancer and other chronic illnesses.

    Time frame: Baseline to Week 8

  11. Time to improvement as measured by rectal bleeding via handheld device

    Time frame: Baseline to Week 8

07

Study locations

1 site
  • Gastroenterology Research of San Antonio (GERSA)
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2022; primary completion for Jul 2023, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2021
First posted
Nov 16, 2021
StartEst.
Dec 30, 2022
Primary completionEst.
Jul 1, 2023
CompletionEst.
Dec 30, 2023
Last update
May 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05121402
Lead sponsor
TLL Pharmaceutical, LLC
Responsible party
Sponsor
First posted
Nov 16, 2021
Start date
Dec 30, 2022 (estimated)
Primary completion
Jul 1, 2023 (estimated)
Completion
Dec 30, 2023 (estimated)
Last update
May 13, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TLL-018

Start the discussion